We’re excited to announce our participation as an exhibitor at the Society for Immunotherapy of Cancer (SITC) 2024, the world’s largest and most comprehensive event focused on advancing cancer immunotherapy science and application. From November 6th to 10th in Houston, this prestigious conference will bring together top experts and innovators to share ideas, gain insights, and drive forward new developments in the field.
What is the Society for Immunotherapy of Cancer 2024?
The Society for Immunotherapy of Cancer (SITC) is the leading global member-driven organization dedicated to professionals in cancer immunotherapy. Its mission is to improve patient outcomes by advancing the science, development, and application of cancer immunology and immunotherapy, guided by our core values of interaction, innovation, translation, and leadership. We strive to make cancer immunotherapy a standard of care and bring the word "cure" within reach for cancer patients everywhere.
Event Overview
Date: November 6th 8:00 am - 10th 12:35 p.m. CST
Venue: George R. Brown Convention Center in Houston, TX & Virtual
Event Schedule
The Society for Immunotherapy of Cancer in Houston will showcase a diverse array of speakers and topics. For a comprehensive look at the daily schedule, including session times and detailed information on each presentation, please refer to the Society for Immunotherapy of Cancer 2024 agenda.
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We look forward to seeing you at the Society for Immunotherapy of Cancer 2024 in Houston!
